Logo image of ACRS

ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

NASDAQ:ACRS - Nasdaq - US00461U1051 - Common Stock - Currency: USD

1.9001  -0.06 (-3.06%)

Fundamental Rating

4

ACRS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While ACRS seems to be doing ok healthwise, there are quite some concerns on its profitability. ACRS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ACRS has reported negative net income.
In the past year ACRS has reported a negative cash flow from operations.
In the past 5 years ACRS always reported negative net income.
ACRS had a negative operating cash flow in each of the past 5 years.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

ACRS has a better Return On Assets (-20.29%) than 60.87% of its industry peers.
Looking at the Return On Equity, with a value of -28.43%, ACRS is in the better half of the industry, outperforming 67.39% of the companies in the same industry.
Industry RankSector Rank
ROA -20.29%
ROE -28.43%
ROIC N/A
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 53.53%, ACRS is in the better half of the industry, outperforming 63.04% of the companies in the same industry.
ACRS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACRS has more shares outstanding
Compared to 5 years ago, ACRS has more shares outstanding
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

ACRS has an Altman-Z score of -3.60. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.60, ACRS is not doing good in the industry: 61.96% of the companies in the same industry are doing better.
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.6
ROIC/WACCN/A
WACC9.81%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

ACRS has a Current Ratio of 7.03. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.03, ACRS is in the better half of the industry, outperforming 73.91% of the companies in the same industry.
ACRS has a Quick Ratio of 7.03. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
ACRS's Quick ratio of 7.03 is fine compared to the rest of the industry. ACRS outperforms 75.54% of its industry peers.
Industry RankSector Rank
Current Ratio 7.03
Quick Ratio 7.03
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.29% over the past year.
The Revenue has grown by 26.36% in the past year. This is a very strong growth!
The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.17%
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Sales Q2Q%-53.18%

3.2 Future

Based on estimates for the next years, ACRS will show a small growth in Earnings Per Share. The EPS will grow by 3.72% on average per year.
The Revenue is expected to grow by 18.07% on average over the next years. This is quite good.
EPS Next Y40.4%
EPS Next 2Y24.45%
EPS Next 3Y12.97%
EPS Next 5Y3.72%
Revenue Next Year-36.68%
Revenue Next 2Y-30.22%
Revenue Next 3Y-25.99%
Revenue Next 5Y18.07%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ACRS's earnings are expected to grow with 12.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.45%
EPS Next 3Y12.97%

More info and screens

0

5. Dividend

5.1 Amount

ACRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (3/4/2025, 11:06:29 AM)

1.9001

-0.06 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners82.79%
Inst Owner Change63.55%
Ins Owners2.53%
Ins Owner Change15.04%
Market Cap203.35M
Analysts84.62
Price Target10.2 (436.81%)
Short Float %4.84%
Short Ratio6.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-880.3%
Min EPS beat(2)-1788.67%
Max EPS beat(2)28.07%
EPS beat(4)3
Avg EPS beat(4)-412.16%
Min EPS beat(4)-1788.67%
Max EPS beat(4)94.31%
EPS beat(8)7
Avg EPS beat(8)-200.46%
EPS beat(12)11
Avg EPS beat(12)-128.13%
EPS beat(16)11
Avg EPS beat(16)-105.33%
Revenue beat(2)1
Avg Revenue beat(2)4.52%
Min Revenue beat(2)-40.15%
Max Revenue beat(2)49.19%
Revenue beat(4)3
Avg Revenue beat(4)123.29%
Min Revenue beat(4)-40.15%
Max Revenue beat(4)412.1%
Revenue beat(8)6
Avg Revenue beat(8)161.35%
Revenue beat(12)7
Avg Revenue beat(12)192.77%
Revenue beat(16)10
Avg Revenue beat(16)146.03%
PT rev (1m)0%
PT rev (3m)31.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.66%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-7.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.51
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.25
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.29%
ROE -28.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.53%
FCFM N/A
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
F-Score6
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.13%
Cap/Sales 2.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.03
Quick Ratio 7.03
Altman-Z -3.6
F-Score6
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)87.21%
Cap/Depr(5y)64.17%
Cap/Sales(3y)3.61%
Cap/Sales(5y)11.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.17%
EPS Next Y40.4%
EPS Next 2Y24.45%
EPS Next 3Y12.97%
EPS Next 5Y3.72%
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Sales Q2Q%-53.18%
Revenue Next Year-36.68%
Revenue Next 2Y-30.22%
Revenue Next 3Y-25.99%
Revenue Next 5Y18.07%
EBIT growth 1Y65.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.12%
EBIT Next 3Y9.49%
EBIT Next 5YN/A
FCF growth 1Y72.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.68%
OCF growth 3YN/A
OCF growth 5YN/A